Ph3 study of pembro in HNSCC in the disease without curative therapy available

Phase III Clinical Trial

A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer
Trial Number: 06525220
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations